TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01930071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PQ Bypass Guide Wire Delivery System
Description: The PQ Bypass Guide Wire Delivery System is used to bypass lesions in the peripheral vasculature percutaneously. A guidewire is placed from the artery proximal to the lesion to the artery distal to the lesion using the vein as a conduit with the Guidewire Delivery System. Once in place, commercially available stent grafts will be placed to complete the bypass.
Study: NCT04632979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Backwards running on a Treadmil with a negative slope
Description: Running backward on a treadmill with a negative slope
Study: NCT01167127

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release
Description: OXN Tablet, oral, BID, flexible dose design
Study: NCT02806401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: landmark

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: US_Ax
Study: NCT02913807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Customized Jigs and Plates
Description: The titanium locking reconstruction plates will be prefabricated based on the preoperative CT scans. Prior to procedure, customized planning for osteotomies will generate the prefabricated jigs.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hand Contoured Osteotomies and Reconstruction Bars
Description: This will be the traditional method of hand-conjuring the bar and bony sites.
Study: NCT00118235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02570477

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Healthy donor is screened and donates feces. It will then be diluted with sterile saline, blended and filtered. Supernatant will be infused to recipient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 125mg Vancomycin four times per day
Study: NCT02702882

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fenugreek Seeds Extract
Description: Furosap one caps OD
Study: NCT01747694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-respiratory muscle training
Description: Patients will be taught the diaphragmatic breathing technique at the same time also will be instructed a four-item (including upper-arm weighted exercise, body side-bends, modified sit-ups, body crunching) multi-respiratory muscle training motions. To practice three times/day, three days a week lasting 12 weeks at home.
Study: NCT03399214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP Injection
Description: T1 and T2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP Injection
Description: T1 and T2
Study: NCT03776058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets for oral administration
Study: NCT01293474

Intervention type: DEVICE
Intervention: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
Description: Measurement of the choroidal thickness with Spectralis® SD-OCT

Intervention type: DEVICE
Intervention: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
Description: Measurement of the choroidal thickness with Spectralis® SD-OCT
Study: NCT02523963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family work shop
Description: 1. The family work shop has 5 courses, with 6 families in one course.~2. One course of intervention: 2-3 hours per session, one time per week, for a total of 6 sessions in 6 week periods
Study: NCT00840476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg Tablets
Description: 1 x 15 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mobic® 15 mg Tablets
Description: 1 x 15 mg, single-dose fasting
Study: NCT00850148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anwar
Description: Anwar surgical method

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Melles
Description: Melles surgical method
Study: NCT00817440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: 3 days of fasting and then the same as arm 1
Study: NCT01112761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Each type of stimulation will be administered with a time interval of a week in between to prevent any carryover affects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Each type of stimulation will be administered with a time interval of a week in between to prevent any carryover affects.
Study: NCT02599558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge
Description: A capsule with a string attached with a sponge inside is swallowed. The string is held without any tension to allow the capsule to move into the stomach. The string will be held for five minutes to allow the capsule to dissolve in the stomach; a round mesh sponge about the size of a quarter is released.
Study: NCT02882776

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ginger drink
Description: Ginger powder dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ginger drink
Description: Ginger powder dissolved in water
Study: NCT03684538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Patients will receive probiotics (Saccharomyces boulardii) one dose per day (250 mg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Patients will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics & Zinc
Description: Patients will receive a combination of probiotics (Saccharomyces boulardii 250 mg) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified
Study: NCT03935880

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cartiva Implant
Description: Cartiva hemiarthroplasty: The procedure starts with a small incision over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected, leaving approximately 2 mm of surrounding bone on the metatarsal head. A guide pin is placed within the metatarsal and a drill is then used to create a site for the implant. The implant is then placed using the implant introducer. The incision is then closed and a sterile dressing is placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cheilectomy
Description: Cheilectomy: A small incision is made over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected. The top of the metatarsal head is then cut with a sagittal saw. Additional bone spurs are resected. The incision is closed and a sterile dressing is placed.
Study: NCT02558491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Decision Support System
Description: The purpose of this study is to demonstrate the safety and feasibility of a Decision Support System aimed at reducing glucose variability in T1DM patient using an insulin pump or MDI. The system will be deployed on our portable medical application platform (DiAs) and will include the following elements:~1. An insulin pump treatment parameters optimization routine, using a month of collected CGM/insulin/meal data~2. An exercise risk warning system, capable of predicting hypoglycemia at the onset of physical activity and advising on mitigating alteration of treatment.~3. A smart bolus calculator based on CGM glucose measurements and insulin sensitivity estimation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: During the Control study admission, DiAs will be programmed with the home insulin dosing parameters. The study subject will use the home basal/bolus MDI or continuous subcutaneous insulin infusion (CSII) insulin regimen via the home insulin pens or pump and determine the amount of insulin to give for the entire admission per the subject's home carb counting parameters and as calculated by the DiAs meal screen.
Study: NCT03523039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb® Hemoadsorption
Description: The therapy is initiated within 6 hours from randomization and maintained for a minimum of 12 consecutive hours to a maximum of 24 consecutive hours.
Study: NCT01307124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kaletra
Description: The study participants will receive Lopinavir/ritonavir heat-stable tablet (100/25 mg or 200/50 mg) q 12 hour plus NRTIs. The other NRTIs is depend on physician discretion.~Arm 1:LPV/r Standard dose Arm 2:Low dose BW 25-35 kg 300/75 mg 200/50 mg BW \>35-50 kg 400/100 mg 300/75 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kaletra
Description: The study participants will receive Lopinavir/ritonavir heat-stable tablet (100/25 mg or 200/50 mg) q 12 hour plus NRTIs. The other NRTIs is depend on physician discretion.~Arm 1:LPV/r Standard dose Arm 2:Low dose BW 25-35 kg 300/75 mg 200/50 mg BW \>35-50 kg 400/100 mg 300/75 mg
Study: NCT00834743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR 750 mg Tablets
Description: 1 x 750 mg, single-dose fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER 750 mg Tablets
Description: 1 x 750 mg, single-dose fasting
Study: NCT04313751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education, Physical Activity, and Stress Management Program
Description: Twelve weekly classes for one hour focused on CVD risk factor education using the Su Corazón Su Vida curriculum and coping skills training followed by a 45 minute exercise class and 15 minute stress management session. Then they will return for one hour for continued support, a forty-five minute exercise class, and fifteen minute stress management session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list
Description: The wait-list control group will receive 12 weekly one hour education and coping skills training sessions followed by a 45 minute exercise class and a 15 minute stress management session.
Study: NCT03730168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: circuit weight training program
Description: 30 male diabetic patients performed circuit weight training for 12 weeks
Study: NCT00830349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 1 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 mg Tablets
Study: NCT00462345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 1000 mg i.v. on Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
Study: NCT02262611

Intervention type: DRUG
Intervention: Micardis®
Study: NCT04617288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Therapy, SNAGs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Therapy, SNAGs
Study: NCT02391805

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Description: Entecavir will be administered as per local labeling.
Study: NCT00462345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid or NSAID
Description: ≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folate
Description: ≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
Study: NCT00542984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide 20 micrograms/day subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmon calcitonin 100 IU/day subcutaneous
Study: NCT03445286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Silver Diamine Fluoride (Advantage Arrest) for the experimental group

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline for the control group
Study: NCT02471963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01430247

Intervention type: OTHER
Group type: OTHER
Intervention: Amblyopia screening
Description: Monocular vision testing at near (40cm) and distance (3m)
Study: NCT00705900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCD
Description: 2 applications / day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcipotriol
Description: 2 applications / day for 12 weeks
Study: NCT03992300

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical adjustment
Description: Accuracy of the framework is checked in the patient mouth by tactile perception, screwing torque, Sheffield test and radiography.
Study: NCT02391805

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Description: Entecavir will be administered as per local labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir will be administered as per local labeling.
Study: NCT03992300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinical adjustment
Description: Accuracy of the framework is checked in the patient mouth by tactile perception, screwing torque, Sheffield test and radiography.
Study: NCT00337051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: General anesthesia using Sevoflurane (inhalation) as hypnotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General anesthesia with propofol TCI
Study: NCT03919240

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Description: Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5\~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).
Study: NCT04420793

Intervention type: OTHER
Intervention: Questionnaire
Description: 3 voice recording tasks and 1 text entry task will be performed.
Study: NCT02391805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir will be administered as per local labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir will be administered as per local labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir will be administered as per local labeling.
Study: NCT01848314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Flowmeasurements will be performed before and after renal denervation
Study: NCT01509027

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education by DVD
Description: Information on detrimental conseqences of hyperphosphatemia is presented on DVD

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: standard care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education by DVD and dietician
Description: Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
Study: NCT03263806

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CTFFR-Guided Group Management
Description: Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results will be communicated to the provider who will use CTFFR interpretation to guide care pathway.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: SOC Group Management
Description: Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results are NOT communicated to the provider who will dictate patient management according to their own clinical judgment
Study: NCT04030195

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PBCAR20A
Description: Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic 3+3 dose escalation will be applied.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PBCAR20A
Description: Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic 3+3 dose escalation will be applied.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PBCAR20A
Description: Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic 3+3 dose escalation will be applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).
Study: NCT02391805

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6864018
Description: Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6864018
Description: Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6864018
Description: Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6864018
Description: Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir will be administered as per local labeling.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir will be administered as per local labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir will be administered as per local labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir will be administered as per local labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir will be administered as per local labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir will be administered as per local labeling.
Study: NCT04030195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).
Study: NCT02109029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Insulin
Description: Administered IV
Study: NCT02262611

Intervention type: DRUG
Intervention: Micardis®

Intervention type: DRUG
Intervention: Micardis®

Intervention type: DRUG
Intervention: Micardis®
Study: NCT03237091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bihemispheric transcranial pulsed current stimulation (tPCS)
Description: Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
Study: NCT01575912

Intervention type: OTHER
Intervention: experimental pain tests

Intervention type: OTHER
Intervention: experimental pain tests

Intervention type: OTHER
Intervention: experimental pain tests